Skip to main content
Premium Trial:

Request an Annual Quote

FDA Seeks Microarray Datasets for Quality Control Project

NEW YORK, April 21 (GenomeWeb News) - the US Food and Drug Administration is soliciting gene expression datasets from microarray experiments as part of its MicroArray Quality Control project.

 

In a notice of solicitation dated April 13 and posted on the FDA website yesterday, FDA said that it is seeking datasets "as well as proposals to analyze these datasets in order to evaluate the impact of different analysis protocols on the selection of genes and their associated signatures for biomarker pattern development."

 

The FDA's NationalCenter for Toxicological Research is collecting the datasets and proposals for participation in the project. The evaluation process is open to the public, FDA said.

 

The MAQC project involves six FDA centers, several microarray vendors, government agencies, and academic labs that are working to develop "baseline practices for the analysis of hybridization data," the FDA said.

 

Further information on the MAQC project is available here.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.